Minapharm Pharmaceuticals S.A.E. specializes in developing, manufacturing and marketing prescription pharmaceutical products. The products are for the treatment of gastroenterological, ophthalmologic, cardiovascular, genetic, dermatological, orthopedic diseases, etc.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
01/10/26	EGP 812.49	+4.21%	1,741
30/09/26	EGP 779.68	-0.90%	2,283
29/09/26	EGP 786.76	-0.64%	4,401
28/09/26	EGP 791.85	+3.37%	14,961
27/09/26	EGP 766.00	-5.42%	9,325

End-of-day quote Egyptian Exchange

More quotes

End-of-day quote Egyptian Exchange 01/10/2026			5-day change	1st Jan Change
812.49 ^EGP	+4.21%		+0.32%	+132.67%

08-27	CEPI backs Minapharm's experimental Ebola vaccine with up to $16.5 million funding	RE
08-27	Minapharm Group Receives Funding to Advance Bundibugyo Ebolavirus Vaccine Candidate to Clinical Trials	CI

Market Cap	9.57B 183M 162M 152M 138M 261M 17.6B 264M 1.84B 711M 8.97B 686M 672M 28.8B	P/E 2024	14x	P/E 2025	584x
Enterprise Value	10.68B 204M 181M 169M 154M 291M 19.65B 295M 2.05B 794M 10.01B 766M 749M 32.14B	EV / Sales 2024	0.78x	EV / Sales 2025	0.81x
Free-Float	14.5%	Yield 2024	1.54%	Yield 2025	-

08-27	CEPI backs Minapharm's experimental Ebola vaccine with up to $16.5 million funding	RE
08-27	Minapharm Group Receives Funding to Advance Bundibugyo Ebolavirus Vaccine Candidate to Clinical Trials	CI
08-17	MINAPHARM Pharmaceuticals Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
06-10	MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-05	Minapharm pharmaceuticals FY standalone net profit EGP 57.5 million	RE
11-30	Minapharm Pharmaceuticals Q3 consol profit egp 16.8 million	RE
11-30	MINAPHARM Pharmaceuticals Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
14/09/25	MINAPHARM Pharmaceuticals Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
14/09/25	Minapharm Pharmaceuticals Q2 consol profit EGP 40 million	RE
27/07/25	MINAPHARM Pharmaceuticals Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
27/07/25	Minapharm Pharmaceuticals Q1 consol net loss EGP 2 million	RE
12/06/25	MINAPHARM Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2024	CI
12/06/25	Minapharm Pharmaceuticals FY Colsol Net Profit EGP 161.1 Million	RE

07/07/25	EBRD, Admaius Capital plan to acquire 15%-20% of Egyptian Minapharm Pharmaceuticals	AQ
26/03/25	African Development Bank Approves Eur 15 Million Loan to Boost Biosimilars' Development and Production in Egypt	AQ
05/10/23	SaudiVax, Minapharm, and MiGenTra Sign a Memorandum of Understanding towards a Strategic Partnership in Saudi Arabia and the Gulf Cooperation Countries	AQ
04/10/23	SaudiVax, Minapharm, and MiGenTra Sign a Memorandum of Understanding towards a Strategic Partnership in Saudi Arabia and the Gulf Cooperation Countries This landmark MOU marks a significant step towards ensuring national health security and achieving biomanufacturing autonomy in Saudi Arabia	AQ
06/03/23	Participants Dosed of Adessia® in Germany in a Phase 1 Trial, a First for an Adalimumab Biosimilar Candidate Developed in Africa	AQ

MINAPHARM Pharmaceuticals Stock

Stocks

MIPH

EGS380G1C011

Pharmaceuticals

Valuation: MINAPHARM Pharmaceuticals

Chart: MINAPHARM Pharmaceuticals

Latest news: MINAPHARM Pharmaceuticals

Press Releases: MINAPHARM Pharmaceuticals

Quotes and Performance

Price Extremes

Managers and Directors: MINAPHARM Pharmaceuticals

Generic Pharmaceuticals

Financials

Company Profile

Quotes

1 day	+4.21%
1 week	+0.32%
Current month	+4.21%
1 month	+1.79%
3 months	+23.40%
6 months	+76.62%
Current year	+132.67%

1 week	739.69	879
1 month	739.69	1,000
Current year	320.23	1,000
1 year	256.45	1,000
3 years	145	1,000
5 years	101.05	1,000
10 years	45	1,000

Manager	Title	Age	Since
Shaheer Wafeeq Sa'ad Al-Bardissy CEO	Chief Executive Officer	-	-
Wafik El-Bardissy CEO	Chief Executive Officer	-	19/10/2010
Rafiq Raymond DFI	Director of Finance/CFO	-	-

Director	Title	Age	Since
Wafik El-Bardissy CHM	Chairman	-	18/10/2010
Anwar Nasr Mekhaeel BRD	Director/Board Member	-	18/10/2010
Amr Mohamed Sobhi Hamza El-Shabrawishy BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MINAPHARM PHARMACEUTICALS	+4.21%	+0.32%	+212.51%	+301.39%	183M
ELI LILLY AND COMPANY	-0.62%	-2.71%	+39.30%	+114.07%	1,025B
JOHNSON & JOHNSON	-2.30%	-4.44%	+39.03%	+66.07%	623B
ABBVIE INC.	-0.63%	-1.96%	+6.36%	+74.38%	459B
MERCK & CO., INC.	-1.03%	-2.82%	+59.56%	+39.69%	355B
ROCHE HOLDING AG	-0.19%	-3.58%	+22.19%	+40.05%	336B
NOVARTIS AG	+0.30%	-1.22%	+13.77%	+26.74%	270B
ASTRAZENECA PLC	+0.02%	-3.84%	-3.08%	+10.23%	247B
AMGEN INC.	-3.38%	+0.30%	+36.44%	+51.54%	220B
GILEAD SCIENCES, INC.	-1.04%	-1.46%	+32.70%	+96.82%	183B
Average	-0.46%	-1.10%	+45.88%	+82.10%	371.84B
Weighted average by Cap.	-0.97%	-2.11%	+30.42%	+69.56%

	2024	2025
Net sales	5.66B 108M 96.11M 89.88M 81.91M 154M 10.42B 156M 1.09B 421M 5.31B 406M 397M 17.04B	6.44B 123M 109M 102M 93.09M 175M 11.84B 178M 1.24B 478M 6.03B 462M 452M 19.37B
Net income	157M 3M 2.66M 2.49M 2.27M 4.28M 289M 4.33M 30.15M 11.67M 147M 11.26M 11.02M 473M	40.22M 768K 682K 638K 581K 1.09M 73.96M 1.11M 7.72M 2.99M 37.67M 2.88M 2.82M 121M
Net Debt	2.6B 49.63M 44.08M 41.22M 37.57M 70.72M 4.78B 71.7M 499M 193M 2.43B 186M 182M 7.82B	1.11B 21.21M 18.83M 17.61M 16.05M 30.22M 2.04B 30.63M 213M 82.49M 1.04B 79.62M 77.89M 3.34B